Skip to search formSkip to main contentSkip to account menu

AZD6094

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

volitinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 4541:METgene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor
There is no approved therapy specifically for the treatment of papillary renal cell carcinoma (PRCC). Advances in molecular… 
2016
2016
Preliminary results of a phase Ib trial of savolitinib combined with gefitinib in EGFR-mutant lung cancer.
e20559Background: Savolitinib (AZD6094, volitinib, HMPL-504) is a potent & selective small molecule MET inhibitor. In preclinical… 
2016
2016
Abstract 1150: Targeting MET Exon 14 mutations with the selective small molecule inhibitor Savolitinib
Alterations in the MET oncogene occurs across a broad range of tumor indications. Amplification or mutations in MET lead to… 
2015
2015
cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell…
487 Background: Met is a receptor tyrosine kinase that is deregulated across multiple cancer types, leading to uncontrolled tumor… 
2015
2015
Abstract 1477: Pharmacodynamic response and anti-tumor activity of the MET inhibitor AZD6094 in papillary renal cell carcinoma patient derived xenograft models
Papillary renal cell carcinoma (PRCC) is the second most common cancer of the kidney and carries a poor prognosis for patients… 
2015
2015
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients with Papillary Renal Cell Carcinoma NCT02127710
2014
2014
392 Using modelling & simulation to integrate mouse PK–PD-efficacy with preliminary human PK data to inform the Phase II doses and schedule for the experimental c-Met inhibitor AZD6094 (Volitinib)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)